Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-05-31
1997-10-21
Hill, Jr., Robert J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530330, A61K 3800, C07K 500
Patent
active
056796439
ABSTRACT:
Compounds of the formula: ##STR1## or a salt thereof, wherein n is 1 or 2;
wherein when n is 1, X is a mono- or disubstituted or unsubstituted C.sub.1-20 hydrocarbon radical wherein any substitution is selected from the group consisting of halo, OR, and SR, wherein R is H or C.sub.1-4 alkyl;
and wherein, when n is 2, one X is defined as for n=1 and the other X is lower C.sub.1-4 alkyl; ##STR2## wherein m is 1 or 2; AA.sub.C is an amino acid coupled through a peptide bond to the remainder of the compound of Formula (1) selected from the group consisting of glycine, valine, alanine, 4-aminobutyric acid, aspartic acid, phenylglycine, histidine, tryptophan, tyrosine, and phenylalanine, wherein the phenyl group of phenylalanine or phenylglycine may optionally contain a single substitution selected from the group consisting of halo, OR, and SR, wherein R is H or C.sub.1-4 alkyl;
with the proviso that if Y is ##STR3## AA.sub.C is not Gly; and if Y is ##STR4## and X is benzyl, AA.sub.C cannot be Val are useful as affinity ligands and as diagnostic reagents. These compounds and analogous tripeptide glutathione analogs can be used as members of panels to obtain specific characteristic profiles for various glutathione-S-transferases.
REFERENCES:
patent: 4963263 (1990-10-01), Kauvar
patent: 5133866 (1992-07-01), Kauvar
Ciaccio P.J. et al. "Modulation of Detoxification Gene Expression in Human Colon HT29 Cells by Glutathione-S-Transferase Inhibitors" Molecular Pharmacology 48:639-647 (1995).
Annual Meeting of the Canadian Society for Clinical Investigation and the Royal College of Physicians and Surgeons of Canda, Montreal, Quebec, Canada, Sep. 13-17, 1995, "Clinical and Investigative Medicine, " vol. 18 (4 Suppl.) (1995), Cournoyer D. et al.
Morgan A. S. et al. "Isozyme-specific Glutathione S-Transferase Inhibitors Potentiate Drug Sensitivity in Cultured Human Tumor Cell Lines," Cancer Chemother. Pharmacol. 37:363-370 (1996).
T. Kasai et al., Phytochemistry "y-Glutamyl Peptides of Vigna Radiata Seeds" vol. 25, pp. 679-682.
R. Camble, et al., J. Chem. Soc. "The Use of S-Benzylthiomethyl-L-cysteine in Peptide Synthesis: Synthesis of Glutathione and Homoglutathione" (1968) 7/1515:1219-1224.
Mozer et al., "Purification and Characterization of Corn Glutathione S-Transferase", Biochemistry 22: 1068-1072 (1983).
Sheh, L., Synthesis of cyclic peptide homologs of glutathione as potential antitumor agents, Int. J. Peptide Protein Res. (1990) 35:55-62.
Webster's II New Riverside University Dictionary, The New Riverside Publishing Company, 1988, p. 849.
Principato et al. (1989) 41: 175-180 Enzyme.
Kauvar Lawrence M.
Lyttle Matthew H.
Celsa Bennett
Hill Jr. Robert J.
Terrapin Technologies, Inc.
LandOfFree
Glutathione analogs and paralog panels comprising glutathione mi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glutathione analogs and paralog panels comprising glutathione mi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glutathione analogs and paralog panels comprising glutathione mi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1006735